MedTrace Logo

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT02242032 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2015-05-04

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.

Conditions

Interventions

DRUG

P-321 Ophthalmic Solution

DRUG

P-321 Ophthalmic Solution placebo

Placebo to match P-321 Ophthalmic Solution

Sponsors & Collaborators

  • Parion Sciences

    lead INDUSTRY

Principal Investigators

  • Kenneth Sall, MD · Sall Research Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02242032 on ClinicalTrials.gov